A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Study Number
3712823
Phase
I
Age Group
Adult
Principal Investigator
Matthew Cortese
Purpose

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

Check your eligibility for this trial
Check now
Full Title

A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies

ClinicalTrials.Gov ID
NCT05006716

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.